Acquisitions (Details) (USD $)	3 Months Ended		6 Months Ended				6 Months Ended			6 Months Ended			6 Months Ended		0 Months Ended	3 Months Ended		3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014 R&D- and commercialization-based milestones [Member]	Jun. 30, 2014 R&D- and commercialization-based milestones [Member] Minimum [Member]	Jun. 30, 2014 R&D- and commercialization-based milestones [Member] Maximum [Member]	Jun. 30, 2014 revenue-based payments [Member] Discounted cash flow [Member]	Jun. 30, 2014 revenue-based payments [Member] Discounted cash flow [Member] Minimum [Member]	Jun. 30, 2014 revenue-based payments [Member] Discounted cash flow [Member] Maximum [Member]	Jun. 30, 2014 revenue-based payments [Member] Monte Carlo [Member]	Jun. 30, 2014 revenue-based payments [Member] Monte Carlo [Member] Minimum [Member]	Jun. 30, 2014 revenue-based payments [Member] Monte Carlo [Member] Maximum [Member]	May 07, 2014 IoGyn [Member]	Jun. 30, 2014 IoGyn [Member]	May 07, 2014 IoGyn [Member]	Jun. 30, 2014 Bayer [Member]	Jun. 30, 2014 Technology-related [Member]	Jun. 30, 2014 Technology-related [Member] IoGyn [Member]	Jun. 30, 2014 Other Intangible Assets [Member]	Jun. 30, 2014 Other Intangible Assets [Member] IoGyn [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired																				$ 71,000,000		$ 1,000,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life																			14 years		2 years
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation																			14.00%		14.00%
Goodwill	5,735,000,000		5,735,000,000		5,693,000,000											39,000,000
Accrued Contingent Consideration	372,000,000		372,000,000		(501,000,000)
Business Combination, Liabilities Arising from Contingencies, Amount Recognized			(3,000,000)	0
Adjustments to accrued contingent consideration			1,000,000
Contingent consideration expense (benefit)	96,000,000	18,000,000	118,000,000	41,000,000
Contingent payment related to business combination			15,000,000
Maximum future contingent consideration for acquisitions	2,200,000,000		2,200,000,000
Business Combination, Contingent Consideration, Liability						(61,000,000)			(69,000,000)			(242,000,000)
Revenue Volatility - Contingent Consideration													11.00%	13.00%
contingent consideration liability, projected year of payment							2014	2015		2014	2018		2014	2018
contingent consideration liability, probability of payment							60.00%	95.00%		0.00%	100.00%
Risk-adjusted discount rate for contingent consideration							0.90%	1.40%		11.50%	15.00%
Minority interest owned of IoGyn																	28.00%
Accounts and Notes Receivable, Net															8,000,000
Payments to Acquire Businesses, Net of Cash Acquired			72,000,000	0											65,000,000			415,000,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable																31,000,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain																19,000,000
Remaining equity of IoGyn purchased																72.00%
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination																96,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles																72,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other																(1,000,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets, Current																(14,000,000)
Payment of contingent consideration	$ (3,000,000)		$ 15,000,000	$ 15,000,000